Lead Product(s) : ATX-304
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATX-304 is a peripherally acting pan-AMPK activator with beneficial effects on glucose and lipid metabolism and energy expenditure in multiple animal models of metabolic disorders, as well as cardiovascular function.
Product Name : ATX-304
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : ATX-304
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1029539
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orexo's Partner Gesynta Pharma Announces Positive Results from Phase 1 Study for OX-MPI
Details : The clinical study was aimed at evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI to healthy subjects after single and multiple ascending dosages.
Product Name : BI 1029539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 15, 2020
Lead Product(s) : BI 1029539
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable